Impact of age on survival in radioiodine refractory differentiated thyroid cancer patients
| Autor: | Laurence Leenhardt, Johanna Wassermann, Camille Buffet, Elise Mathy, Nathalie Chereau, Clotilde Saie, S. Tezenas du Montcel |
|---|---|
| Přispěvatelé: | CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Tezenas du Montcel, Sophie |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Aging medicine.medical_specialty Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Adenocarcinoma Gastroenterology Metastasis Iodine Radioisotopes 03 medical and health sciences 0302 clinical medicine Endocrinology Refractory Internal medicine medicine Clinical endpoint Humans Thyroid Neoplasms Treatment Failure Progression-free survival Thyroid cancer Survival analysis Aged Neoplasm Staging Retrospective Studies business.industry Age Factors Mediastinum Retrospective cohort study General Medicine Middle Aged Prognosis medicine.disease Survival Analysis Treatment Outcome medicine.anatomical_structure [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie 030220 oncology & carcinogenesis Disease Progression Female [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie France business |
| Zdroj: | European Journal of Endocrinology European Journal of Endocrinology, 2021, 184 (5), pp.667-676. ⟨10.1530/EJE-20-1073⟩ |
| ISSN: | 0804-4643 1479-683X |
| DOI: | 10.1530/EJE-20-1073⟩ |
| Popis: | Objective The objectives of our study were to analyze the influence of age on the survival of patients with RAIR-DTC and to determine their prognostic factors according to age. Methods This single-center, retrospective study enrolled 155 patients diagnosed with RAIR-DTC. The primary end point was overall survival (OS) according to different cutoff (45, 55, 65, 75 years). Secondary endpoints were progression free survival (PFS) and prognostic factors in patients under and over 65 years. Results Median OS after RAIR diagnosis was 8.2 years (95% IC: 5.3–9.6). There was no difference according to age with a 65 (P = 0.47) and 55 years old cutoff (P = 0.28). Median OS improved significantly before 45 years old (P = 0.0043). After 75 years old, median OS significantly decreased (P = 0.0008). Median PFS was 2.1 years (95% CI: 0.8–3) in patients < 65 years old, and 1 year in patients ≥ 65 years old (95% CI: 0.8–1.55) with no statistical difference (P = 0.22). There was no impact of age on PFS with any cutoff. In both groups, progressive disease despite 131I treatment reduced OS. In patients < 65 years old, an interval of less than 3 years between the initial diagnosis and the diagnosis of RAIR metastatic disease was predictive of poor survival. In patients > 65 years old, the presence of a mediastinum metastasis was a significant factor for mortality (HR: 4.55, 95% CI: 2.27–9.09). Conclusion In RAIR-DTC patients, a cut-off age of 65 years old was not a significant predictive factor of survival. Forty-five and 75-years-old cutoff were predictive for OS but not PFS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|